Login to Your Account



Valeant Buying Out Xcel's Neurology Line For $280M

By Randall Osborne


Friday, February 4, 2005
About this time last year, Xcel Pharmaceuticals Inc. bought the rights to the Phase III-ready epilepsy drug retigabine from Viatris GmbH and Co., of Frankfurt, Germany. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription